Plant Name: Scopolia japonica
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| CHRM2; DRD1; CHRM5; CHRM1; HTR6; CHRM3; | |
| RECQL; TDP1; BLM; MTOR; AKR1B1; GFER; HSD17B10; AKR1B10; ALDH1A1; POLB; | |
| CA9; CA1; CA12; ODC1; CA13; CA7; | |
| MT-ND4; | |
| CASP1; CASP7; | |
| TP53; NFKB1; | |
| LMNA; MAPT; PMP22; GMNN; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | ODC1 | Ornithine decarboxylase | P11926 | CHEMBL1869 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Oxidoreductase | MT-ND4 | NADH-ubiquinone oxidoreductase chain 4 | P03905 | CHEMBL4499 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Small molecule receptor (family A GPCR) | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | CHEMBL211 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 | CHEMBL2035 |
| Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Small molecule receptor (family A GPCR) | CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 | CHEMBL245 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | PMP22 | Peripheral myelin protein 22 | Q01453 | CHEMBL1293298 |
| Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0007197; adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway | 5.687E-11 | 4.184E-07 | CHRM1, CHRM2, CHRM3, CHRM5 |
| MF | GO:0060089; molecular transducer activity | GO:0016907; G-protein coupled acetylcholine receptor activity | 5.687E-11 | 4.184E-07 | CHRM1, CHRM2, CHRM3, CHRM5 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.764E-11 | 4.184E-07 | CA1, CA12, CA13, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0007207; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway | 1.704E-10 | 9.275E-07 | CHRM1, CHRM2, CHRM3, CHRM5 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.030E-09 | 2.551E-05 | CA1, CA12, CA13, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.003E-08 | 4.934E-05 | CA1, CA12, CA13, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.289E-07 | 1.559E-04 | CYP1A2, CYP2C19, CYP2D6 |
| BP | GO:0023052; signaling | GO:0007271; synaptic transmission, cholinergic | 1.937E-07 | 2.220E-04 | CHRM1, CHRM2, CHRM3, CHRM5 |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 5.392E-07 | 5.591E-04 | BLM, RECQL, TP53 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 6.546E-07 | 6.197E-04 | AKR1B1, BLM, CASP7, DRD1, MTOR, NFKB1, TP53, TSHR |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 6.958E-06 | 4.456E-03 | BLM, CA9, CASP1, CASP7, CYP1A2, DRD1, MTOR, NFKB1, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 7.769E-06 | 4.833E-03 | AKR1B1, BLM, CA9, CASP1, DRD1, MTOR, NFKB1, POLB, TP53 |
| BP | GO:0050896; response to stimulus | GO:0009628; response to abiotic stimulus | 1.349E-05 | 7.343E-03 | AKR1B1, BLM, CASP1, DRD1, LMNA, MAPT, MTOR, NFKB1, POLB, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004435; phosphatidylinositol phospholipase C activity | 1.833E-05 | 9.512E-03 | CHRM1, CHRM3, CHRM5 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 9.959E-11 | 1.215E-08 | CA12; CA1; CA7; CA9; CA13 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 6.539E-07 | 3.666E-05 | CHRM2; CHRM3; HTR6; CHRM1; CHRM5; DRD1; TSHR |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 9.015E-07 | 3.666E-05 | CHRM2; CHRM3; HTR6; CHRM1; CHRM5; DRD1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.618E-06 | 4.935E-05 | CHRM2; HTR6; CHRM1; DRD1; NFKB1; TSHR |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 5.153E-05 | 1.257E-03 | CHRM2; CHRM3; CHRM1; CHRM5 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.270E-04 | 2.494E-03 | CASP7; LMNA; TP53; NFKB1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.431E-04 | 2.494E-03 | CASP7; CASP1; NFKB1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.896E-04 | 4.753E-03 | CHRM2; CHRM1; TP53; NFKB1; MTOR |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.807E-04 | 4.281E-03 | CYP2D6; CYP1A2; CYP2C19 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.932E-04 | 6.488E-03 | TP53; NFKB1; MTOR |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 6.382E-04 | 6.488E-03 | CHRM2; CHRM3; CHRM1; CHRM5 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 3.591E-04 | 4.753E-03 | CASP7; CASP1; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 6.958E-04 | 6.530E-03 | TP53; NFKB1; MTOR |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.156E-03 | 1.008E-02 | HTR6; CYP2D6; CYP2C19 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.668E-03 | 2.262E-02 | CASP7; MAPT; HSD17B10 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 6.381E-03 | 2.711E-02 | POLB; TP53; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 6.888E-03 | 2.711E-02 | AKR1B10; ODC1; CYP1A2; ALDH1A1; AKR1B1; CYP2C19; HSD17B10 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 4.985E-03 | 2.644E-02 | NFKB1; MTOR |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 3.708E-03 | 2.262E-02 | DRD1; NFKB1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 6.437E-03 | 2.711E-02 | TP53; MTOR |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.310E-03 | 1.066E-02 | CYP1A2; CYP2C19 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 4.010E-03 | 2.330E-02 | CASP1; TP53 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 5.332E-03 | 2.711E-02 | AKR1B10; AKR1B1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.402E-03 | 1.069E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.017E-03 | 1.367E-02 | AKR1B10; AKR1B1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 4.985E-03 | 2.644E-02 | CASP1; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 6.631E-03 | 2.711E-02 | TP53; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.156E-02 | 3.617E-02 | MAPT; TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 6.437E-03 | 2.711E-02 | CYP1A2; ALDH1A1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.827E-03 | 2.711E-02 | TP53; MTOR |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 6.246E-03 | 2.711E-02 | CASP1; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.193E-02 | 3.640E-02 | POLB; TP53; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 8.058E-03 | 2.891E-02 | TP53; NFKB1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.595E-03 | 1.145E-02 | AKR1B10; AKR1B1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 7.431E-03 | 2.833E-02 | NFKB1; MTOR |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.736E-02 | 4.883E-02 | TP53; NFKB1; MTOR |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 8.058E-03 | 2.891E-02 | CYP2D6; CYP1A2 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.104E-02 | 3.544E-02 | TP53; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.556E-02 | 4.629E-02 | NFKB1; MTOR |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.731E-02 | 4.883E-02 | NFKB1; MTOR |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.761E-02 | 4.883E-02 | CASP7; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.008E-02 | 3.415E-02 | CYP1A2; CYP2C19 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.104E-02 | 3.544E-02 | CASP1; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 9.217E-03 | 3.213E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1 |
| NA: NA | Functional bowel syndrome | NA | CHRM1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | CHRM5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | CHRM2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | MTOR; CA9 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | CHRM3 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CHRM1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | CHRM1; CHRM5; HTR6 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Seborrhea | L21 | CHRM3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR6 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MTOR |
| NA: NA | Abdominal stomach pain | NA | CHRM1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CHRM1; CHRM1; CHRM1; DRD1; CHRM5; HTR6 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | CHRM1; CHRM2; CHRM5; CHRM3 |
| NA: NA | Schizoaffective disorders | NA | CHRM1 |
| C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; AKR1B1 |
| A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| C00-D49: Neoplasms | Solid tumors | NA | MTOR |
| NA: NA | Spasms | NA | CHRM3 |
| C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Sjogren's syndrome | M35.0 | CHRM3 |
| NA: NA | Addiction | NA | CHRM2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Stabilize muscle contractions | M00-M99 | CHRM2 |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1; CHRM5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | TP53; CA1; MTOR; CA9; NFKB1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnosing bronchial hyperreactivity | W88 | CHRM3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR6; HTR6 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | CHRM5 |
| NA: NA | Dystonia | NA | CHRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | CHRM1 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1 |
| NA: NA | Excessive sweating | NA | CHRM1 |
| NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | CHRM5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Postoperative nausea and vomiting | R11 | CHRM3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Amnesia | F04 | CHRM5 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | CHRM1; CHRM2; MAPT; HTR6; HTR6; HTR6; CHRM3 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | CHRM1; DRD1; HTR6 |
| C00-D49: Neoplasms | Bladder cancer | C67 | MTOR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | CHRM2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | ODC1; TP53; AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MTOR; DRD1; CHRM3 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; MTOR; CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain diseases | G00-G99 | CHRM5 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MTOR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | CHRM2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Burns and burn infection | A00-B99 | ODC1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CHRM1; CA1; CA1; AKR1B1; CHRM3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CHRM2 |
| A00-B99: Certain infectious and parasitic diseases | African trypanosomiasis | B56 | ODC1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | CHRM5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | MTOR; CA9 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MTOR |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; DRD1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | MTOR; MTOR |
| N00-N99: Diseases of the genitourinary system | Overactive bladder | N32.81 | CHRM3 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1; CHRM3 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | CHRM1; CHRM5; CHRM3 |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM1; CHRM5 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| NA: NA | Coronary artery restenosis | NA | MTOR |
| J00-J99: Diseases of the respiratory system | Obstructive lung diseases | J40-J44, J47 | CHRM3 |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | CHRM1; CHRM2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | CHRM1; CHRM1; CHRM2; DRD1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MTOR |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | CHRM1; DRD1; CHRM5; MAPT; HTR6 |
| K00-K95: Diseases of the digestive system | Colitis | K50-K52 | CHRM5 |